Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a five year prospective study

Annals of the Rheumatic Diseases

Volumn 57, Issue 2, 1998, Pages 88-93

  Munro, Robin ^a   Hampson, Rosie ^a   McEntegart, Anne ^a   Thomson, E Anne ^a   Madhok, Rajan ^a   Capell, Hilary ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0031966835     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.57.2.88     Document Type: Article

References (28)

1. Bensen WG, Bensen W, Adachi JD. Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol 1997;24:1023-7.
2. Kelly WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 2nd ed. Philadelphia: Saunders, 1985: 979.
3. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessments in rheumatoid arthritis. J Rheumatol 1991;18:1290-7.
4. Fries JF, Williams CA, Ramey D, Block DA. The relative toxicity of disease-modifying anti-rheumatic drugs. Arthritis Rheum 1993;36:297-306.
5. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
6. van der Heijde A, Jacobs JWG, Bijlsma WJ, Heurkens AH, van Booma-Frankford C, van der Veen MJ, et al. The effectiveness of early treatment "second-line" anti rheumatic drugs: a randomised, controlled trial. Ann Intern Med 1996;124: 699-707.
7. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford health assessment questionnaire functional disability index in patients with rheumatoid arthritis. J Rheumatol 1988;15: 1480-8.
8. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991;18:1307-12.
9. Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multi-centre controlled trial. Ann Rheum Dis 1961;20:315-52.
10. Sigler JW, Bluhm GB, Duncan H, Sharp JJ, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974;80: 21-6.
11. Luukkainen R, Kajander A, Isomaki H. Effect of gold on progression of erosions in rheumatoid arthritis: better results with earlier treatment. Scand J Rheumatol 1977;6: 189-92.
12. Ropes WN, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
13. Fries JF, Spitt PW, Kraines RG. Measurements of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
14. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
15. Hakala M, Nieminen P, Koivisto O. More evidence from a community based series of better outcome in rheumatoid arthritis. Data on the effect of multidisciplinary care on the retention of functional ability. J Rheumatol 1994;21: 1432-7.
16. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
17. American College Of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
18. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
19. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
20. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, van de Putt LBA. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
21. Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997;24:1285-7.
22. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
23. Young A. Short-term outcomes in recent-onset rheumatoid arthritis. Br J Rheumatol 1995;34 (suppl 2):79-86.
24. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22:2208-13.
25. Situnayake RD, McKonkey B. Clinical and laboratory effects of prolonged therapy with sulphasalazine, gold or penicillamine: the effects of disease duration on treatment response. J Rheumatol 1990;17:1268-73.
26. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1440-61.
27. Epstein WV. Parenteral gold therapy for rheumatoid arthritis: a treatment whose time has gone. J Rheumatol 1989;16:1291-4.
28. Harrison BJ, Symmons DPM, Brennan P, Bankhead CR, Barrett EM, Scott DG, et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol 1996;23:1326-31.